Edition:
United Kingdom

Sartorius Stedim Biotech Q1 Sales Revenue Up 19.3% To 342.9 Million Euros


Thursday, 18 Apr 2019 

April 18 (Reuters) - SARTORIUS STEDIM BIOTECH SA ::Q1 SALES REVENUE UP 19.3%; ORDER INTAKE UP 18.7%; EARNINGS MARGIN 28.6%.GUIDANCE FOR 2019 CONFIRMED.SALES REVENUE INCREASED AGAINST RELATIVELY MODERATE COMPARABLES IN THE PRIOR-YEAR QUARTER BY 19.3% TO 342.9 MILLION EUROS.Q1 ORDER INTAKE ALSO SAW A SIGNIFICANT UPTICK, RISING 18.7% TO 381.3 MILLION EUROS.Q1 UNDERLYING EBITDA1 ROSE OVERPROPORTIONATELY RELATIVE TO SALES BY 32.5% TO 98.1 MILLION EUROS.THE Q1 RESPECTIVE MARGIN REACHED 28.6% (Q1 2018: 26.3%).Q1 RELEVANT NET PROFIT AFTER NON-CONTROLLING INTEREST FOR THE GROUP SURGED BY 32.9% TO 62.6 MILLION EUROS.WE EXPECT THAT GROWTH RATES WILL NORMALIZE OVER THE COURSE OF THE YEAR. ON THIS BASIS WE CONFIRM OUR 2019 FULL-YEAR GUIDANCE - CEO.SEES CONSOLIDATED SALES REVENUE IS PROJECTED TO GROW BY ABOUT 7% TO 11% IN 2019.EXPECTS COMPANY'S UNDERLYING 2019 EBITDA MARGIN TO INCREASE BY SLIGHTLY MORE THAN ONE PERCENT.